Resource problems, drug safety issues "challenged" EMA in 2011
This article was originally published in SRA
Executive Summary
2011 was more of a mixed bag than usual for the European Medicines Agency, as budget pressures and the need to prioritise the new pharmacovigilance legislation led it to make efficiency improvements and put some projects on the back burner1.